Plain-English translation of NCT04469764 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called , which is designed to target specific genetic changes in cancer cells. The study focuses on people whose ovarian or endometrial cancer has come back after previous treatment and whose tumors have certain genetic markers that this medication is designed to work against. Researchers want to see how well the medication works and how safe it is for these patients.
Many people with recurrent ovarian and endometrial cancer have limited treatment options after their initial chemotherapy. This trial exists to explore whether this medication—which targets specific genetic drivers in these cancers—might offer a new, more personalized treatment option for patients whose tumors have the right genetic features.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth twice daily in 28-day cycles for as long as it helps your cancer and you tolerate it well. If your tumor is hormone-sensitive, you would also receive an additional hormone therapy medication. You would have regular clinic visits for blood tests and imaging scans to monitor how well the treatment is working. After you stop taking the medication, you would have follow-up visits at 30 days, and then every 12 weeks for up to one year.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States